Amarin’s REDUCE-IT Data Could Spillover To These Names
Insights - Amarin (AMRN) will present data from their cardiovascular (CV) outcome REDUCE-IT trial on November 10. This data caused AMRN shares to jump from $3 – … Continue Reading
Read nowMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
Early Data Supports Oncosec Ahead of 2 Catalysts in 2018
Insights - ONCS has two ipcoming catalysts with PICES data in November for metastatic melanoma and OMS-140 data for TNBC in December. Prior data (discussed below) leads … Continue Reading
Read now
News of Patient Death Has No Impact on Selecta’s Lead Program
Insights - Selecta released an 8-K after market today which disclosed that one of the patients in the SEL-403 trial died from a Grade 5 Serious Adverse … Continue Reading
Read now
Bellus Well Positioned Following Menlo’s Cough Flop
Insights - Menlo (MNLO), a company developing serlopitant for chronic cough candidate, reported disappointing Phase 2 data. In 185 patients, serlopitant group had 31% less reduction than the placebo group. In … Continue Reading
Read nowWhat to Expect from Selecta’s Phase 2 data in October 2018
Insights - Selecta will present their “5+0” co-administered Phase 2 data at the American College Rheumatology (ACR) conference held October 19-24 in Chicago. What to expect 1. … Continue Reading
Read now
FDA Under Enormous Pressure To Approve Fennec’s STS Drug Under Wide Label Following Testimony At Little-Known Patient Advocacy Event on September 13
Insights - For the first time since PropThink launched in late 2012, we travelled to a Patient Advocacy Meeting in Maryland – to see and hear from … Continue Reading
PremiumLow Data Hurdle Makes Bellus Attractive Ahead of Q4 Catalyst
Insights - In December, Bellus Health (BLUSF:OTC) (BLU:TSX) will report Phase 1 data for their chronic cough candidate BLU-5937. Bellus’ candidate is a P2X3 inhibitor, a class … Continue Reading
Read now